Progress in application of positron emission tomography/computed tomography (PET/CT) imaging in tumor screening
LU Xiaoqian1, ZONG Lingyan2, SHEN Qi1
1. Department of Medical Devices, Changzhou Second People’s Hospital Affiliated to Nanjing Medical University, Changzhou 213001 China; 2. Department of Equipment and Material Purchase and Supervision, Changzhou Municipal First People’s Hospital, Changzhou 213004 China
[1] Weissleder R, Mahmood U. Molecular imaging[J]. Radiology, 2001, 219(2): 316-333. DOI: 10.1148/radiology.219.2.r01ma19316 [2] Chen K, Chen XY. Design and development of molecular imaging probes[J]. Curr Top Med Chem, 2010, 10(12): 1227-1236. DOI: 10.2174/156802610791384225 [3] Gatidis S, Hepp T, Früh M, et al. A whole-body FDG-PET/CT dataset with manually annotated tumor lesions[J]. Sci Data, 2022, 9(1): 601. DOI: 10.1038/s41597-022-01718-3 [4] Huang ZY, Zou SJ, Wang GS, et al. ISA-Net: improved spatial attention network for PET-CT tumor segmentation[J]. Comput Methods Programs Biomed, 2022, 226: 107129. DOI: 10.1016/j.cmpb.2022.107129 [5] Furlow B. PET-CT cancer imaging[J]. Radiol Technol, 2018, 90(2): 149CT-170CT [6] Teramoto A, Yamada A, Tsukamoto T, et al. Decision support system for lung cancer using PET/CT and microscopic images[J]. Adv Exp Med Biol, 2020, 1213: 73-94. DOI: 10.1007/978-3-030-33128-3_5 [7] Cheebsumon P, Boellaard R, de Ruysscher D, et al. Assessment of tumour size in PET/CT lung cancer studies: PET-and CT-based methods compared to pathology[J]. EJNMMI Res, 2012, 2(1): 56. DOI: 10.1186/2191-219X-2-56 [8] Evangelista L, Sepulcri M, Pasello G. PET/CT and the response to immunotherapy in lung cancer[J]. Curr Radiopharm, 2020, 13(3): 177-184. DOI: 10.2174/1874471013666191220105449 [9] Yossi S, Krhili S, Muratet JP, et al. Early assessment of metabolic response by 18F-FDG PET during concomitant radiochemotherapy of non-small cell lung carcinoma is associated with survival: a retrospective single-center study[J]. Clin Nucl Med, 2015, 40(4): e215-e221. DOI: 10.1097/RLU.0000000000000615 [10] Na F, Wang JW, Li C, et al. Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis[J]. J Thorac Oncol, 2014, 9(6): 834-842. DOI: 10.1097/JTO.0000000000000185 [11] Voigt W. Advanced PET imaging in oncology: status and developments with current and future relevance to lung cancer care[J]. Curr Opin Oncol, 2018, 30(2): 77-83. DOI: 10.1097/CCO.0000000000000430 [12] Khiewvan B, Ziai P, Houshmand S, et al. The role of PET/CT as a prognosticator and outcome predictor in lung cancer[J]. Expert Rev Respir Med, 2016, 10(3): 317-330. DOI: 10.1586/17476348.2016.1147959 [13] Kim R, Prithviraj G, Kothari N, et al. PET/CT fusion scan prevents futile laparotomy in early stage pancreatic cancer[J]. Clin Nucl Med, 2015, 40(11): e501-e505. DOI: 10.1097/RLU.0000000000000837 [14] Kauhanen SP, Komar G, Seppänen MP, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer[J]. Ann Surg, 2009, 250(6): 957-963. DOI: 10.1097/SLA.0b013e3181b2fafa [15] Lytras D, Connor S, Bosonnet L, et al. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer[J]. Dig Surg, 2005, 22(1/2): 55-62. DOI: 10.1159/000085347 [16] Liu XY, Ren Y, Wang JY, et al. The clinical diagnostic value of F-FDG PET/CT combined with MRI in pancreatic cancer[J]. Contrast Media Mol Imaging, 2022, 2022: 1479416. DOI: 10.1155/2022/1479416 [17] Nie CH, Zhang YL, Zhou GH, et al. Analysis of the efficacy of transcatheter arterial infusion chemotherapy in the treatment of pancreatic carcinoma[J]. J Interv Med, 2021, 4(1): 21-26. DOI: 10.1016/j.jimed.2020.10.005 [18] Patel SH, Edwards MJ, Ahmad SA. Intracellular ion channels in pancreas cancer[J]. Cell Physiol Biochem, 2019, 53(S1): 44-51. DOI: 10.33594/000000193 [19] Toyama Y, Hotta M, Motoi F, et al. Prognostic value of FDG-PET radiomics with machine learning in pancreatic cancer[J]. Sci Rep, 2020, 10(1): 17024. DOI: 10.1038/s41598-020-73237-3 [20] Jeong YJ, Kang DY, Yoon HJ, et al. Additional value of F-18 FDG PET/CT for initial staging in breast cancer with clinically negative axillary nodes[J]. Breast Cancer Res Treat, 2014, 145(1): 137-142. DOI: 10.1007/s10549-014-2924-8 [21] Paydary K, Seraj SM, Zadeh MZ, et al. The evolving role of FDG-PET/CT in the diagnosis, staging, and treatment of breast cancer[J]. Mol Imaging Biol, 2019, 21(1): 1-10. DOI: 10.1007/s11307-018-1181-3 [22] Segaert I, Mottaghy F, Ceyssens S, et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer[J]. Breast J, 2010, 16(6): 617-624. DOI: 10.1111/j.1524-4741.2010.00987.x [23] Davidson T, Shehade N, Nissan E, et al. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases[J]. Surg Oncol, 2021, 38: 101567. DOI: 10.1016/j.suronc.2021.101567 [24] Rong J, Wang SY, Ding QE, et al. Comparison of 18FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis[J]. Surg Oncol, 2013, 22(2): 86-91. DOI: 10.1016/j.suronc.2013.01.002 [25] Hogan MP, Goldman DA, Dashevsky B, et al. Comparison of 18F-FDG PET/CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma[J]. J Nucl Med, 2015, 56(11): 1674-1680. DOI: 10.2967/jnumed.115.161455 [26] Sollini M, Cozzi L, Ninatti G, et al. PET/CT radiomics in breast cancer: mind the step[J]. Methods, 2021, 188: 122-132. DOI: 10.1016/j.ymeth.2020.01.007 [27] Zhang XJ, Guan Z. PET/CT in the diagnosis and prognosis of osteosarcoma[J]. Front Biosci (Landmark Ed), 2018, 23(11): 2157-2165. DOI: 10.2741/4696 [28] Dancheva Z, Bochev P, Chaushev B, et al. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma[J]. Nucl Med Rev Cent East Eur, 2016, 19(1): 22-27. DOI: 10.5603/NMR.2016.0005 [29] Chang KJ, Kong CB, Cho WH, et al. Usefulness of increased 18F-FDG uptake for detecting local recurrence in patients with extremity osteosarcoma treated with surgical resection and endoprosthetic replacement[J]. Skeletal Radiol, 2015, 44(4): 529-537. DOI: 10.1007/s00256-014-2063-7 [30] Liu B, Yang H, Servaes S, et al. Solitary retroperitoneal metastasis as the initial site of the relapse of osteosarcoma revealed by FDG PET/CT[J]. Clin Nucl Med, 2015, 40(11): 892-894. DOI: 10.1097/RLU.0000000000000796 [31] Chou YH, Ko KY, Cheng MF, et al. 18F-NaF PET/CT images of cardiac metastasis from osteosarcoma[J]. Clin Nucl Med, 2016, 41(9): 708-709. DOI: 10.1097/RLU.0000000000001289 [32] Byun BH, Kong CB, Lim I, et al. Comparison of (18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma[J]. Skeletal Radiol, 2013, 42(12): 1673-1681. DOI: 10.1007/s00256-013-1714-4 [33] Al Hatmi A, Jain A, Mittal AK, et al. Evaluation of diagnostic value of SPECT/CT imaging in post-radioiodine therapy in thyroid cancer[J]. Sultan Qaboos Univ Med J, 2022, 22(1): 74-81. DOI: 10.18295/squmj.4.2021.054 [34] Ruers TJM, Wiering B, van der Sijp JRM, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with 18F-FDG PET: a randomized study[J]. J Nucl Med, 2009, 50(7): 1036-1041. DOI: 10.2967/jnumed.109.063040 [35] Heinrich S, Goerres GW, Schäfer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness[J]. Ann Surg, 2005, 242(2): 235-243. DOI: 10.1097/01.sla.0000172095.97787.84 [36] Farma JM, Santillan AA, Melis M, et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms[J]. Ann Surg Oncol, 2008, 15(9): 2465-2471. DOI: 10.1245/s10434-008-9992-0
